GlaxoSmithKline LLC /
RAPT Therapeutics, Inc.
GSK's unit completes takeover of RAPT Therapeutics




Source for the buyer and target: RAPT Therapeutics, Inc.
For the buyer and target.
“Agreement and Plan of Merger, dated as of January 19, 2026, by and among RAPT Therapeutics, Inc., GlaxoSmithKline LLC, Redrose Acquisition Co. and, solely for purposes of Section 8.11 thereto, GSK plc (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed by RAPT Therapeutics, Inc. on January 20, 2026 (File No. 001-38997)).”
Published 3 Mar 2026
Open the sourceWhat happened
GlaxoSmithKline LLC has finished its tender offer and merger for RAPT Therapeutics, Inc., which now operates as a direct wholly owned subsidiary of the buyer. The merger was carried out on March 3, 2026, under Section 251(h) of Delaware law, without a stockholder vote. [01]
Under the deal, RAPT shareholders were set to receive $58.00 per share in cash. RAPT's stock was delisted from Nasdaq, and its board was replaced with new directors and officers. [01]
The source
Everything on this page comes from the source below, quoted word for word.
GSK's unit completes takeover of RAPT Therapeutics
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Also stated
“The merger was carried out on March 3, 2026, under Section 251(h) of Delaware law, without a stockholder vote”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly